Skip to main content
SUTRO BIOPHARMA, INC. logo

SUTRO BIOPHARMA, INC. — Investor Relations & Filings

Ticker · STRO ISIN · US8693671021 LEI · 5493005U6P15VD25P851 US Manufacturing
Open in API
Filings indexed 585 across all filing types
Latest filing 2023-05-15 Earnings Release
Country US United States of America
Listing US STRO

About SUTRO BIOPHARMA, INC.

https://www.sutrobio.com/

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of precisely designed cancer therapeutics. The company leverages its proprietary, integrated cell-free protein synthesis platform to create novel antibody-drug conjugates (ADCs). This technology enables the development of next-generation ADCs, including those with single and dual payloads, which are designed to offer improved therapeutic profiles for patients with cancer. Sutro is advancing its own pipeline of clinical-stage product candidates to address areas of significant unmet medical need.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 15, 2023, by Sutro Biopharma, Inc. It announces the issuance of a press release regarding financial results for the quarter ended March 31, 2023. The document itself does not contain the financial results but references an attached press release (Exhibit 99.1). The length is 3655 characters, which is relatively short and consistent with an announcement rather than a full report. The document explicitly states that the information is being furnished and is not deemed "filed" for certain legal purposes, indicating it is an announcement rather than the full earnings release. Therefore, this document is best classified as an Earnings Release (ER) announcement, as it announces quarterly financial results. However, since the actual financial results are in the attached press release, and the 8-K is the official filing of that announcement, the best fit is Earnings Release (ER).
2023-05-15 English
FORM 4 SUBMISSION
Director's Dealing
2023-05-03 English
FORM 3 SUBMISSION
Director's Dealing
2023-05-03 English
ARS
Annual Report
2023-04-28 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a Proxy Statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. It includes information about the upcoming Annual Meeting, voting instructions, election of directors, ratification of auditors, executive compensation advisory vote, and amendments to the certificate of incorporation. The document is not the Annual Report itself, nor is it a report publication announcement. It is a definitive proxy statement or related materials for shareholder voting purposes. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI). The document length is 4773 characters, which is consistent with a proxy statement or proxy materials rather than a full annual report or other filings.
2023-04-28 English
DEF 14A
Proxy Solicitation & Information Statement
2023-04-28 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.